INAUGURAL POST

Nonpartisan pharma news and views from the horse’s mouth, not the jockey’s

A Short Journey Back to the Future

I thought to reproduce this inaugural post from Inside Pharma, dated January 21st 2022. At the time, there were 123 subscribers (if you are one of them, please make yourself known :O)):

“WE NEED TO KNOW THIS WILL GET PROPER REGULATORY SCRUTINY

Hot on the heels of the Pfizer/BioNTech SARS-CoV-2 injection comes the next candidates for mRNA treatment – Shingles.

In an article published in PHARMACEUTICAL TECHNOLOGY, titled Pfizer and BioNTech enter deal to develop first mRNA vaccine for shingles, January 6, 2022, the deal was described by Pfizer Worldwide Research, Development & Medical chief scientific officer and president Mikael Dolsten as so: “With this agreement, we continue on our journey of discovery together, by advancing mRNA technology to tackle another health challenge ripe for scientific innovation, supported by our world-class manufacturing network.”

Inside Pharma says:

Given there is no rationale for an emergency approval, this MUST go through th…